News about Global Pharma

IQVIA and Boehringer Ingelheim Partner on Global Commercial Data Transformation

The long-term strategic collaboration aims to modernise Boehringer Ingelheim’s global commercial data foundation, enabling scalable, advanced analytics across therapeutic areas and regions using IQVIA’s industry-leading data model.

Global Pharma | 31/01/2026 | By News Bureau |  310

Innovent's Tri-Specific Antibody IBI3003 Secures FDA Fast Track Status for Relapsed/Refractory Multiple Myeloma

Innovent Biologics’ tri-specific antibody IBI3003 has received FDA Fast Track Designation for heavily pretreated relapsed or refractory multiple myeloma, supported by promising early clinical efficacy and safety data.

Global Pharma | 27/01/2026 | By News Bureau |  236

Abbott Secures CE Mark for TactiFlex Duo Ablation Catheter to Treat Atrial Fibrillation in Europe

Abbott has received CE Mark approval for its TactiFlex Duo Ablation Catheter, enabling dual-energy AFib treatment in Europe and marking successful first commercial procedures across the EU.

Global Pharma | 21/01/2026 | By News Bureau |  232

Zylox-Tonbridge to Acquire Germany's Optimed in a Move to Expand Global Vascular Devices Footprint

Multi-step acquisition of Optimed strengthens Zylox-Tonbridge’s European footprint, R&D capabilities and global commercialisation of minimally invasive vascular solutions.

Global Pharma | 17/01/2026 | By News Bureau |  386

Boston Scientific to Acquire Penumbra in USD 14.5 Billion Deal to Expand Vascular and Neurovascular Portfolio

Boston Scientific will acquire Penumbra in a USD 14.5 billion cash and stock deal to expand its vascular and neurovascular portfolio, strengthening its position in thrombectomy, stroke, and cardiovascular disease treatment markets.

Global Pharma | 17/01/2026 | By News Bureau |  252

FDA Grants 510(k) Clearance for Updated BEAR Implant Label, Showing Reduced Risk of Post-Traumatic Osteoarthritis After ACL Injury

Miach Orthopaedics’ BEAR Implant becomes the first sports medicine device to carry an FDA-cleared claim for lowering long-term osteoarthritis risk compared with traditional ACL reconstruction.

Global Pharma | 16/01/2026 | By News Bureau |  472

Leadoptik Secures FDA 510(k) Clearance for Last Inch Assessment System to Enhance Lung Biopsy Accuracy

The silicon photonics based imaging platform, Leadoptik’s LIA system, delivers real-time, high-resolution tissue insight at the point of care, addressing a critical gap in lung cancer diagnosis.

Global Pharma | 16/01/2026 | By News Bureau |  510

Novo Nordisk Foundation Awards DKK 5.5 Billion to Boost Innovation in Denmark and Europe

The Novo Nordisk Foundation has awarded DKK 5.5 billion to support innovation in Denmark and Europe, enabling BioInnovation Institute (BII) to expand into new strategic areas and geographies. The funding aims to back a larger number of entrepreneurs and start-ups, strengthening the region’s life sciences and innovation ecosystem.

Global Pharma | 16/01/2026 | By News Bureau |  141

Sanofi Warns of Near-Term Weakness in US Vaccine Demand Amid Antivax Rhetoric

French pharmaceutical company Sanofi expects near-term weakness in vaccine sales in the United States, attributing the anticipated softness to growing scepticism around immunizations that the company says has been fueled by misinformation.

Global Pharma | 15/01/2026 | By Darshana |  226

Bayer Targets Return to Mid-Single-Digit Pharma Growth by 2027

Addressing investors at a major healthcare conference, Stefan Oelrich, head of Bayer’s pharmaceuticals business, said the company expects 2026 to be the final year significantly affected by the loss of exclusivity on its blockbuster anticoagulant Xarelto. From 2027 onward, Bayer anticipates a recovery driven by newer medicines and pipeline progress.

Global Pharma | 14/01/2026 | By Darshana |  707